comprises fulvestrant in solution,15-25 % weight of
a pharmaceutically-acceptable alcohol per volume of formulation, 10-25 % weight of a pharmaceutically-acceptable nonaqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least 45 mgml-1 of fulvestrant.
19. Use of fulvestrant in the preparation of a pharmaceutical formulation for the treatment of breast cancer by intra-muscular administration to human patients, wherein the pharmaceutical
formulation